oncology

Prenatal exposure to high doses of folic acid associated with increased risk of cancer in children of mothers with epilepsy |  Medicine in 2 Minutes

Prenatal exposure to high doses of folic acid associated with increased risk of cancer in children of mothers with epilepsy | Medicine in 2 Minutes

1. Cancer risk was higher in children of mothers with epilepsy who were exposed to high doses of folic acid in utero compared to controls in this retrospective study. 2. There was no association between maternal antiepileptic drug use and cancer risk. Assessment of the level of proof: 2 (good) Summary of the study: Epilepsy …

Prenatal exposure to high doses of folic acid associated with increased risk of cancer in children of mothers with epilepsy | Medicine in 2 Minutes Read More »

Nucleai and Propath partnership paves the way for spatial biomarkers in oncology

Nucleai and Propath partnership paves the way for spatial biomarkers in oncology

3D rendering of the CAF layer of cancer-associated fibroblasts on the tumor microenvironment. [Marcin Klapczynski/Getty Images] Space biologists Nucleai and Propath UK have announced a partnership to develop and validate an immunofluorescence assay focused on 30 immuno-oncology protein targets that could inform the development of novel oncology biomarkers and companion diagnostics. Dr. Ken Bloom, Head …

Nucleai and Propath partnership paves the way for spatial biomarkers in oncology Read More »

Combined treatment with avelumab and axitinib for advanced type B3 thymoma and thymic carcinoma shows promise as second-line therapy after standard treatment.  |  Medicine in 2 Minutes

Combined treatment with avelumab and axitinib for advanced type B3 thymoma and thymic carcinoma shows promise as second-line therapy after standard treatment. | Medicine in 2 Minutes

1. Patients who had never received anti-angiogenesis therapy had longer progression-free survival 2. Adverse effects of the combination of avelumab and axitinib are mild and include abdominal pain, diarrhea, nausea and vomiting. Level of evidence assessment: 2 (Good) Summary of the study: Type B3 thymoma and thymic carcinoma are aggressive tumors with poor survival outcomes …

Combined treatment with avelumab and axitinib for advanced type B3 thymoma and thymic carcinoma shows promise as second-line therapy after standard treatment. | Medicine in 2 Minutes Read More »